AU2016254498B2 - Nucleic acid construct - Google Patents

Nucleic acid construct Download PDF

Info

Publication number
AU2016254498B2
AU2016254498B2 AU2016254498A AU2016254498A AU2016254498B2 AU 2016254498 B2 AU2016254498 B2 AU 2016254498B2 AU 2016254498 A AU2016254498 A AU 2016254498A AU 2016254498 A AU2016254498 A AU 2016254498A AU 2016254498 B2 AU2016254498 B2 AU 2016254498B2
Authority
AU
Australia
Prior art keywords
leu
glu
asp
ser
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016254498A
Other languages
English (en)
Other versions
AU2016254498A1 (en
Inventor
Shaun CORDOBA
Martin Pule
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Autolus Ltd
Original Assignee
Autolus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autolus Ltd filed Critical Autolus Ltd
Publication of AU2016254498A1 publication Critical patent/AU2016254498A1/en
Assigned to UCL BUSINESS LTD reassignment UCL BUSINESS LTD Amend patent request/document other than specification (104) Assignors: UCL BUSINESS PLC
Application granted granted Critical
Publication of AU2016254498B2 publication Critical patent/AU2016254498B2/en
Assigned to Autolus Limited reassignment Autolus Limited Request for Assignment Assignors: UCL BUSINESS LTD
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/06—Fusion polypeptide containing a localisation/targetting motif containing a lysosomal/endosomal localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2016254498A 2015-04-27 2016-04-26 Nucleic acid construct Ceased AU2016254498B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1507104.6 2015-04-27
GBGB1507104.6A GB201507104D0 (en) 2015-04-27 2015-04-27 Nucleic acid construct
PCT/GB2016/051164 WO2016174408A1 (en) 2015-04-27 2016-04-26 Nucleic acid construct

Publications (2)

Publication Number Publication Date
AU2016254498A1 AU2016254498A1 (en) 2017-11-09
AU2016254498B2 true AU2016254498B2 (en) 2020-10-22

Family

ID=53488689

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016254498A Ceased AU2016254498B2 (en) 2015-04-27 2016-04-26 Nucleic acid construct

Country Status (10)

Country Link
US (1) US11530420B2 (cg-RX-API-DMAC10.html)
EP (1) EP3288968B1 (cg-RX-API-DMAC10.html)
JP (2) JP6836515B2 (cg-RX-API-DMAC10.html)
CN (1) CN107532176A (cg-RX-API-DMAC10.html)
AU (1) AU2016254498B2 (cg-RX-API-DMAC10.html)
CA (1) CA2984101A1 (cg-RX-API-DMAC10.html)
ES (1) ES2847698T3 (cg-RX-API-DMAC10.html)
GB (1) GB201507104D0 (cg-RX-API-DMAC10.html)
HK (1) HK1244021A1 (cg-RX-API-DMAC10.html)
WO (1) WO2016174408A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3805371A1 (en) 2014-05-15 2021-04-14 National University of Singapore Modified natural killer cells and uses thereof
GB201507108D0 (en) 2015-04-27 2015-06-10 Ucl Business Plc Nucleic acid construct
AU2016317936A1 (en) * 2015-09-04 2018-03-08 Tocagen Inc. Recombinant vectors comprising 2A peptide
CN118581046A (zh) 2016-11-22 2024-09-03 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
AU2018240556B2 (en) * 2017-03-24 2025-02-27 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-CD33 immunotherapy
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
CN117363636A (zh) 2017-03-27 2024-01-09 新加坡国立大学 一种编码嵌合受体的多核苷酸
WO2019081750A1 (en) * 2017-10-27 2019-05-02 Statens Serum Institut VACCINE AGAINST POLYGENIC INFLUENZA
CN108359014A (zh) * 2018-02-08 2018-08-03 四川农业大学 含有dhav-1 2a1-p的多肽及其介导的多蛋白共表达方法
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
US12441787B2 (en) 2018-04-02 2025-10-14 National University Of Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
GB201805918D0 (en) 2018-04-10 2018-05-23 Autolus Ltd Cell
EP3841116A4 (en) * 2018-08-24 2022-05-25 Locanabio, Inc. FASL IMMUNOMODULATING GENE THERAPY COMPOSITIONS AND METHODS OF USE
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
CN113226340A (zh) 2018-11-26 2021-08-06 恩卡尔塔公司 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
GB201914611D0 (en) * 2019-10-09 2019-11-20 Autolus Ltd Engineered immune cell
WO2024197792A1 (en) * 2023-03-31 2024-10-03 Beijing University Of Chinese Medicine A complex comprising a cell penetrating peptide and a copi sorting inhibitor and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
WO2013185552A1 (zh) * 2012-06-12 2013-12-19 中国人民解放军第二军医大学东方肝胆外科医院 双信号独立的嵌合抗原受体及其用途
WO2014079878A1 (en) * 2012-11-21 2014-05-30 Merz Pharma Gmbh & Co. Kgaa Means and methods for determination of botulinum neurotoxin biological activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001503260A (ja) * 1996-10-23 2001-03-13 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 改良されたワクチン
EP3104866A4 (en) * 2014-02-14 2017-08-02 Bellicum Pharmaceuticals, Inc. Methods for activating t cells using an inducible chimeric polypeptide
EA037575B1 (ru) 2015-01-26 2021-04-15 Юнайтед Стейтс Минерал Продактс Компани Коррозионно-стойкие напыляемые огнестойкие материалы

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007014162A2 (en) * 2005-07-21 2007-02-01 Abbott Laboratories Multiple gene expression including sorf constructs and methods with polyproteins, pro-proteins, and proteolysis
WO2013185552A1 (zh) * 2012-06-12 2013-12-19 中国人民解放军第二军医大学东方肝胆外科医院 双信号独立的嵌合抗原受体及其用途
WO2014079878A1 (en) * 2012-11-21 2014-05-30 Merz Pharma Gmbh & Co. Kgaa Means and methods for determination of botulinum neurotoxin biological activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
A. EL AMRANI, "Coordinate Expression and Independent Subcellular Targeting of Multiple Proteins from a Single Transgene", PLANT PHYSIOLOGY., US, (2004-05-01), vol. 135, no. 1, doi:10.1104/pp.103.032649, ISSN 0032-0889, pages 16 - 24 *
DE FELIPE PABLO, "Skipping the co-expression problem: the new 2A CHYSEL technology", GENETIC VACCINES AND THERAPY, BIOMED CENTRAL, LONDON, GB, (2004-09-13), vol. 2, no. 1, doi:10.1186/1479-0556-2-13, ISSN 1479-0556, page 13 *
FELIPE DE P ET AL, "Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences", TRAFFIC, MUNKSGAARD, DK, (2004-08-01), vol. 5, no. 8, pages 616 - 626 *
GARRY A. LUKE ET AL, "Self-Processing Polyproteins: A Strategy for Co-expression of Multiple Proteins in Plants", BIOTECHNOLOGY AND GENETIC ENGINEERING REVIEWS, GB, (2006-12-01), vol. 23, no. 1, pages 239 - 252 *
PABLO DE FELIPE ET AL, "Inhibition of 2A-mediated 'cleavage' of certain artificial polyproteins bearing N-terminal signal sequences", BIOTECHNOLOGY JOURNAL, DE, (2009-11-27), vol. 5, no. 2, pages 213 - 223 *

Also Published As

Publication number Publication date
ES2847698T3 (es) 2021-08-03
US20180100163A1 (en) 2018-04-12
HK1244021A1 (zh) 2018-07-27
JP2020171313A (ja) 2020-10-22
EP3288968A1 (en) 2018-03-07
JP2018514208A (ja) 2018-06-07
CN107532176A (zh) 2018-01-02
WO2016174408A1 (en) 2016-11-03
AU2016254498A1 (en) 2017-11-09
CA2984101A1 (en) 2016-11-03
JP6836515B2 (ja) 2021-03-03
EP3288968B1 (en) 2020-11-25
US11530420B2 (en) 2022-12-20
GB201507104D0 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
EP3288968B1 (en) Nucleic acid construct
EP3288582B1 (en) Nucleic acid construct
EP3288970B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
EP3288969B1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
US20180111993A1 (en) Nucleic acid construct for expressing more than one chimeric antigen receptor
KR102174280B1 (ko) 키메라 항원 수용체
EP1676920B1 (en) Anticoagulant fusion protein anchored to cell membrane
CN114555789A (zh) 工程化免疫细胞
WO2022167798A1 (en) Molecule
US20180371056A1 (en) Multi-Span Chimeric Antigen Receptor

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: UCL BUSINESS LTD

Free format text: FORMER NAME(S): UCL BUSINESS PLC

PC1 Assignment before grant (sect. 113)

Owner name: AUTOLUS LIMITED

Free format text: FORMER APPLICANT(S): UCL BUSINESS LTD

MK25 Application lapsed reg. 22.2i(2) - failure to pay acceptance fee
FGA Letters patent sealed or granted (standard patent)
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO PAY THE ACCEPTANCE FEE HAS BEEN EXTENDED TO 22 FEB 2021

MK14 Patent ceased section 143(a) (annual fees not paid) or expired